Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 11/20 | 0.67 |
| ▸ | UHRF1 | Q96T88 | 2/20 | 0.54 |
| ▸ | MYC | P01106 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL14778261 | 0.94 | UHRF1 (0.64) | APEX1UHRF1MYCKDM4EPOLB | |
| SCHEMBL13833744 | 0.81 | APEX1 (0.61) | APEX1UHRF1MYCKDM4EMAPT | |
| SCHEMBL13735036 | 0.80 | APEX1 (1.00) | APEX1UHRF1MYCKDM4EPOLB | |
| SCHEMBL13833708 | 0.80 | APEX1 (0.56) | APEX1UHRF1KDM4EPOLBMAPT | |
| SCHEMBL13833774 | 0.80 | APEX1 (0.56) | APEX1UHRF1KDM4EPOLBMAPT | |
| SCHEMBL14788045 | 0.78 | APEX1 (0.85) | APEX1UHRF1MYCKDM4EPOLB | |
| Hydrochloric Acid SCHEMBL14777450 | 0.78 | APEX1 (0.83) | APEX1UHRF1MYCKDM4EPOLB | |
| Trifluoroacetic Acid SCHEMBL14777866 | 0.75 | UHRF1 (0.90) | APEX1UHRF1MYCKDM4EPOLB | |
| SCHEMBL13833686 | 0.75 | APEX1 (0.51) | APEX1UHRF1KDM4EPOLBMAPT | |
| SCHEMBL13833863 | 0.75 | APEX1 (0.89) | APEX1UHRF1MYCKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| WO-2012154888-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | HSPA5, PSMG3, VCP | APEX1 2669/4885UHRF1 3008/4885MYC 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.